Peptomyc’s business model consists of de-risking Omomyc-CPP from a Proof of Concept Development Stage into a successful Phase I/II product and then Licensing it to a Pharmaceutical company.
Peptomyc is currently looking for investors in order to fund the clinical development of Omomyc.
